Kymera Therapeutics Share Price Today
(NASDAQ: KYMR)

Name: Kymera Therapeutics Share Price Today (NASDAQ: KYMR) - Kymera Therapeutics Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Kymera Therapeutics share price is $36.81 & ₹3,192.38 as on 22 Feb 2025, 2.30 'hrs' IST

$36.81

▲

-0.61

(-1.63%)

Market is closed - opens 8 PM, 24 Feb 2025

View live Kymera Therapeutics share price in Dollar and Rupees. Guide to invest in Kymera Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Kymera Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Kymera Therapeutics share price movements

Today's Low: $36.19
Today's High: $38.90
$36.81
1.68%
Downside
Day's Volatility :6.97%
Upside
5.37%
52 Weeks Low: $29.24
52 Weeks High: $53.27
$36.81
20.57%
Downside
52 Weeks Volatility :45.11%
Upside
30.9%

Kymera Therapeutics (KYMR) Returns

Period	Kymera Therapeutics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-21.71%	1.6%	0.0%
6 Months	-26.01%	-5.8%	0.0%
1 Year	-15.26%	-1.0%	0.0%
3 Years	-6.43%	15.7%	-9.0%

Kymera Therapeutics (KYMR) Key Statistics

in dollars & INR

Previous Close	$37.42
Open	$38.37
Today's High	$38.9
Today's Low	$36.19
Market Capitalization	$2.4B
Today's Volume	$394.1K
52 Week High	$53.27
52 Week Low	$29.24
Revenue TTM	$87.6M
EBITDA	$-190.5M
Earnings Per Share (EPS)	$-2.34
Profit Margin	-191.26%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-26.0%

How to invest in Kymera Therapeutics Stock (KYMR) from India?

It is very easy for Indian residents to invest directly in Kymera Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Kymera Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Kymera Therapeutics or KYMR on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Kymera Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Kymera Therapeutics shares which would translate to 0.024 fractional shares of Kymera Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Kymera Therapeutics, in just a few clicks!

Returns in Kymera Therapeutics (KYMR) for Indian investors in Rupees

The Kymera Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Kymera Therapeutics investment value today

Current value as on today

₹89,387

Returns

₹10,613

(-10.61%)

Returns from Kymera Therapeutics Stock

₹15,262 (-15.26%)

Dollar Returns

₹4,649 (+4.65%)

Indian investors sentiment towards Kymera Therapeutics (KYMR)

-17%

Period: Jan 23, 2025 to Feb 22, 2025. Change in 30 Days versus previous period

Search interest for Kymera Therapeutics Stock from India on INDmoney has decreased by -17% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Kymera Therapeutics

T. Rowe Price Associates, Inc.
10.26%
Baker Bros Advisors LP
9.26%
Wellington Management Company LLP
8.19%
Bvf Inc
7.97%
venBio Select Advisor LLC
7.95%
FMR Inc
7.89%

Analyst Recommendation on Kymera Therapeutics

Buy

69%Buy

30%Hold

0%Sell

Based on 23 Wall street analysts offering stock ratings for Kymera Therapeutics(by analysts ranked 0 to 5 stars)

Based on 23 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Kymera Therapeutics Stock (KYMR)

What analysts predicted

Upside of 59.85%

Target:

$58.84

Current:

$36.81

Insights on Kymera Therapeutics Stock (Ticker Symbol: KYMR)

Price Movement
In the last 1 month, KYMR stock has moved down by -16.8%
Decreasing Revenue
Revenue is down for the last 2 quarters, 25.65M → 3.74M (in $), with an average decrease of 85.4% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -42.06M → -62.48M (in $), with an average decrease of 48.6% per quarter
KYMR vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 59.0% return, outperforming this stock by 71.0%
KYMR vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 69.9% return, outperforming this stock by 67.5%
Price to Sales
ForKYMR every $1 of sales, investors are willing to pay $29.3, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.2 for every $1 of sales.

Kymera Therapeutics Technicals Summary

Sell

Neutral

Buy

Kymera Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Kymera Therapeutics (KYMR) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Kymera Therapeutics Inc	-17.02%	-26.01%	-15.26%	-6.43%	10.67%
Biontech Se	1.58%	37.14%	28.33%	-22.1%	258.88%
Regeneron Pharmaceuticals, Inc.	3.63%	-41.61%	-29.21%	14.85%	58.32%
Vertex Pharmaceuticals Incorporated	10.15%	0.33%	11.71%	110.31%	110.54%
Alnylam Pharmaceuticals, Inc.	-10.11%	-6.89%	57.94%	63.9%	110.07%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Kymera Therapeutics Inc	NA	NA	NA	-2.84	-0.26	-0.15	NA	13.79
Biontech Se	160.8	NA	0.04	-3.29	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	18.16	18.16	1.01	43.09	0.16	0.07	0.01	273.57
Vertex Pharmaceuticals Incorporated	32.84	NA	1.3	18.11	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.59	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Kymera Therapeutics Inc	Buy	$2.4B	10.67%	NA	-191.26%
Biontech Se	Buy	$28.3B	258.88%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$76.1B	58.32%	18.16	31.07%
Vertex Pharmaceuticals Incorporated	Buy	$123.3B	110.54%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$32.5B	110.07%	NA	-12.37%

Kymera Therapeutics Dividend announcements

Kymera Therapeutics Earnings
Kymera Therapeutics’s price-to-earnings ratio stands at None
Read More

About Kymera Therapeutics

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Organization	Kymera Therapeutics
Employees	184
CEO	Dr. Nello Mainolfi M.D., Ph.D.
Industry	Health Technology

Management People of Kymera Therapeutics

Name	Title
Dr. Bruce L. Booth DPHIL, Ph.D.	Co-Founder & Independent Chairman
Dr. Nello Mainolfi M.D., Ph.D.	Co-Founder, President, CEO & Director
Mr. Bruce N. Jacobs CFA	Chief Financial Officer
Dr. Jeremy G. Chadwick Ph.D.	Chief Operating Officer
Ms. Ellen V. Chiniara Esq., J.D.	Chief Legal Officer & Corporate Secretary
Dr. Jared A. Gollob M.D.	Chief Medical Officer
Ms. Karen Weisbach	Head of People & Culture
Dr. Juliet Williams B.A Ph.D.	Head of Research

Important FAQs about investing in KYMR Stock from India :

What is Kymera Therapeutics share price today?

Kymera Therapeutics share price today stands at $36.81, Open: $38.37 ; Previous Close: $37.42 ; High: $38.90 ; Low: $36.19 ; 52 Week High: $53.27 ; 52 Week Low: $29.24.

The stock opens at $38.37, after a previous close of $37.42. The stock reached a daily high of $38.90 and a low of $36.19, with a 52-week high of $53.27 and a 52-week low of $29.24.

Can Indians buy Kymera Therapeutics shares?

Yes, Indians can invest in the Kymera Therapeutics (KYMR) from India.

With INDmoney, you can buy Kymera Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Kymera Therapeutics at zero transaction cost.

How can I buy Kymera Therapeutics shares from India?

It is very easy to buy Kymera Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Kymera Therapeutics (KYMR) be purchased?

Yes, you can buy fractional shares of Kymera Therapeutics with INDmoney app.

What are the documents required to start investing in Kymera Therapeutics stocks?

To start investing in Kymera Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.